Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2024

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Presenter: Jonathan Los

October 27, 2024

Presentation TCT 2023

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

Presenter: Sanjit Jolly

October 25, 2023

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Advertisement

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

STEMI Pharmacotherapy: Oral and IV Antiplatelet Therapies, Intracoronary Lytic, Anticoagulants, and Early PCSK9 Inhibitors

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Role of PCSK9 Inhibitors Post-PCI and ACS

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content